ProfileGDS5678 / 1424920_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 43% 43% 45% 44% 45% 42% 57% 47% 37% 43% 41% 43% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.031843
GSM967853U87-EV human glioblastoma xenograft - Control 23.0060343
GSM967854U87-EV human glioblastoma xenograft - Control 32.9985243
GSM967855U87-EV human glioblastoma xenograft - Control 42.981945
GSM967856U87-EV human glioblastoma xenograft - Control 52.9754844
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1317345
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0222642
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4514157
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1005947
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8381537
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9879643
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9043841
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0025843
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9959643